RT Journal Article
T1 Dendrimers as Innovative Radiopharmaceuticals in Cancer Radionanotherapy
A1 Liko, Flonja
A1 Hindré, François
A1 Fernández Megía, Eduardo
K1 Dendrimers
K1 Radiomedicine
K1 Radiotherapy
K1 Cancer
K1 Radioimmunotherapy
AB Radiotherapy is one of the most commonly used cancer treatments, with an estimate of 40% success that could be improved further if more efficient targeting and retention of radiation at the tumor site were achieved. This review focuses on the use of dendrimers in radionanotherapy, an emerging technology aimed to improve the efficiency of radiotherapy by implementing nanovectorization, an already established praxis in drug delivery and diagnosis. The labeling of dendrimers with radionuclides also aims to reduce the dose of radiolabeled materials and, hence, their toxicity and tumor resistance. Examples of radiolabeled dendrimers with alpha, beta, and Auger electron emitters are commented, along with the use of dendrimers in boron neutron capture therapy (BNCT). The conjugation of radiolabeled dendrimers to monoclonal antibodies for a more efficient targeting and the application of dendrimers in gene delivery radiotherapy are also covered
PB American Chemical Society
SN 1525-7797
YR 2016
FD 2016
LK http://hdl.handle.net/10347/16953
UL http://hdl.handle.net/10347/16953
LA eng
NO Liko, F., Hindré, F., & Fernandez-Megia, E. (2016). Dendrimers as Innovative Radiopharmaceuticals in Cancer Radionanotherapy. Biomacromolecules, 17(10), 3103-3114. doi: 10.1021/acs.biomac.6b00929
NO This work was financially supported by the Spanish Government (CTQ2015-69021-R, CTQ2012-34790) and the Xunta de Galicia (GRC2014/040) and by the “Institut National de la Santé et de la Recherche Médicale” (INSERM), by the “Axe Vectorisation and Radiothérapies” and the “Réseau Gliome Grand Ouest” (ReGGO) of the“Cancéropôle Grand-Ouest”. The coauthors of this manuscript are also members of the LabEx IRON “Innovative Radiopharmaceuticals in Oncologyand Neurology” as part of the french government program “Investissements d’Avenir”. F.L. thanks the European Commission, Education, Audiovisual and Cultural Executive Agency (EACEA) for an Erasmus Mundus Grant under the NanoFar Joint Doctoral Program
DS Minerva
RD 3 may 2026